Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model

Song,Ningning; Guo,Hulin; Ren,Jia; Hao,Suhong; Wang,Xinchao

doi:10.3892/ol.2018.8188

Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model

Authors:
- Ningning Song
- Hulin Guo
- Jia Ren
- Suhong Hao
- Xinchao Wang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Fourth Center Clinical College of Tianjin Medical University, Tianjin 300140, P.R. China, Department of Integrated Traditional Chinese and Western Medicine, The Fifth People's Hospital of Qinghai Province, Xining, Qinghai 810007, P.R. China, Department of Oncology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China
Published online on: March 7, 2018 https://doi.org/10.3892/ol.2018.8188
Pages: 6831-6838
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy is currently considered as one of the major anti‑tumor modalities, but its efficacy is limited. Dasatinib could improve the expansion and recruitment of cluster of differentiation (CD) 8+T cells and natural killer (NK) cells to the tumor microenvironment. The present study aimed to evaluate the synergistic anti‑tumor effects of dasatinib with dendritic cell (DC) vaccine in metastatic breast cancer. Dasatinib with DC vaccine was administered to mice inoculated with 4T1 breast cancer cells. Thereafter, tumor volume was measured every other day. On day 34, lung metastasis was assessed with a stereomicroscope. Tumor proliferation and angiogenesis were determined by immunohistochemistry. Apoptosis in tumor tissues was assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling. The results showed that although there were no significant differences in tumor volumes between the untreated control, DC vaccine and dasatinib groups, the tumor volume was significantly decreased in the combined treatment group compared to the other three groups. Mice in the combined treatment group showed the longest survival time, while mice treated with either single treatment had a slightly increased survival time compared to the untreated control mice. Additionally, the number of metastatic lung nodules was significantly decreased in combined treatment group compared with the dasatinib alone, DC vaccine alone and untreated control groups. Furthermore, the combined treatment group showed significantly reduced intratumoral microvessel density compared to the other three groups. In addition, the ratios of CD8+ T and NK cells were significantly increased in the combined treatment group compared with the other three groups. These results suggest that dasatinib combined with the DC vaccine is a possible modality for the treatment of metastatic breast cancer.

View Figures

View References

1	Balkwill F and Coussens LM: Cancer: An inflammatory link. Nature. 431:405–406. 2004. View Article : Google Scholar : PubMed/NCBI
2	Wang N, Reeves KJ, Brown HK, Fowles ACM, Docherty FE, Ottewell PD, Croucher PI, Holen I and Eaton CL: The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. J Exp Clin Cancer Res. 34:1242015. View Article : Google Scholar : PubMed/NCBI
3	Larkin JR, Dickens AM, Claridge TD, Bristow C, Andreou K, Anthony DC and Sibson NR: Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics. 6:2161–2169. 2016. View Article : Google Scholar : PubMed/NCBI
4	Sun DW, Zhang HD, Mao L, Mao CF, Chen W, Cui M, Ma R, Cao HX, Jing CW, Wang Z, et al: Luteolin inhibits breast cancer development and progression in vitro and in vivo by suppressing notch signaling and regulating MiRNAs. Cell Physiol Biochem. 37:1693–1711. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K and Mustjoki S: Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 116:772–782. 2010. View Article : Google Scholar : PubMed/NCBI
6	Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al: Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 27:914–924. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga G, Bennett KL and Rix U: Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther. 13:2751–2762. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM and Storkus WJ: Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 3:e275892014. View Article : Google Scholar : PubMed/NCBI
9	Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, et al: Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: Results of the D-first study. Am J Hematol. 90:819–824. 2015. View Article : Google Scholar : PubMed/NCBI
10	Shimura Y, Horiike S, Tsutsumi Y, Hatsuse M, Okano A, Fuchida S, Kobayashi T, Matsumoto Y, Kuroda J, Kawata-Iida E, et al: The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib. Int J Hematol. 102:426–433. 2015. View Article : Google Scholar : PubMed/NCBI
11	Christiansson L, Soderlund S, Mangsbo S, Hjorth-Hansen H, Hoglund M, Markevarn B, Richter J, Stenke L, Mustjoki S, Loskog A and Olsson-Strömberg U: The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 14:1181–1191. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ and Lipton JH: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 94:135–139. 2009. View Article : Google Scholar : PubMed/NCBI
13	Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O and Goldstein LJ: Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study. Clin Cancer Res. 17:6905–6913. 2011. View Article : Google Scholar : PubMed/NCBI
14	Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, et al: A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol. 22:2575–2581. 2011. View Article : Google Scholar : PubMed/NCBI
15	Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT and Cortes J: Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004. Clin Cancer Res. 19:1884–1893. 2013. View Article : Google Scholar : PubMed/NCBI
16	Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T and Daud AI: Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 106:85–91. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wolfl M, Schwinn S, Yoo YE, Ress ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, et al: Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood. 122:1203–1213. 2013. View Article : Google Scholar : PubMed/NCBI
18	Nerreter T, Köchel C, Jesper D, Eichelbrönner I, Putz E, Einsele H and Seggewiss-Bernhardt R: Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Exp Hematol. 42(773–782): e1–3. 2014.
19	Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, Liu Y, Woodman SE and Hwu P: Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120:4533–4543. 2012. View Article : Google Scholar : PubMed/NCBI
20	Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995. View Article : Google Scholar : PubMed/NCBI
21	Lee F, Jure-Kunkel MN and Salvati ME: Synergistic activity of ixabepilone plus other anticancer agents: Preclinical and clinical evidence. Ther Adv Med Oncol. 3:11–25. 2011. View Article : Google Scholar : PubMed/NCBI
22	Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT and Cortes J: Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004. Clin Cancer Res. 19:1884–93. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chen J, Zhao Y, Chu X, Lu Y, Wang S and Yi Q: Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy. Oncoimmunology. 5:e12385582016. View Article : Google Scholar : PubMed/NCBI
24	Schietinger A and Greenberg PD: Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol. 35:51–60. 2014. View Article : Google Scholar : PubMed/NCBI
25	Makkouk A and Weiner GJ: Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res. 75:5–10. 2015. View Article : Google Scholar : PubMed/NCBI
26	Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST and Wu H: Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 34:2017–2028. 2014. View Article : Google Scholar : PubMed/NCBI
27	Keskinov AA and Shurin MR: Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology. 220:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
28	Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol. 166:678–689. 2001. View Article : Google Scholar : PubMed/NCBI
29	Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
30	Blake S, Hughes TP, Mayrhofer G and Lyons AB: The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 127:330–339. 2008. View Article : Google Scholar : PubMed/NCBI
31	Blake SJ, Bruce LA, Fraser CK, Hayball JD and Hughes TP: Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 111:4415–4416. 2008. View Article : Google Scholar : PubMed/NCBI
32	Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H and Maciejewski JP: Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 111:1366–1377. 2008. View Article : Google Scholar : PubMed/NCBI
33	Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al: Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 14:2484–2491. 2008. View Article : Google Scholar : PubMed/NCBI
34	Valent JN and Schiffer CA: Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res. 35:e1–e3. 2011. View Article : Google Scholar : PubMed/NCBI
35	Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP and Lin PC: Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6:409–421. 2004. View Article : Google Scholar : PubMed/NCBI
36	Heine A, Held SA, Bringmann A, Holderried TA and Brossart P: Immunomodulatory effects of anti-angiogenic drugs. Leukemia. 25:899–905. 2011. View Article : Google Scholar : PubMed/NCBI
37	Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A and Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 7:345–356. 2007. View Article : Google Scholar : PubMed/NCBI
38	Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 14:6674–6682. 2008. View Article : Google Scholar : PubMed/NCBI
39	Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
40	Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69:2514–2522. 2009. View Article : Google Scholar : PubMed/NCBI
41	Xin H, Zhang C, Herrmann A, Du Y, Figlin R and Yu H: Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
42	Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH and Storkus WJ: Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer. 129:2158–2170. 2011. View Article : Google Scholar : PubMed/NCBI
43	Bose A, Lowe DB, Rao A and Storkus WJ: Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res. 22:236–243. 2012. View Article : Google Scholar : PubMed/NCBI
44	Yuan H, Cai P, Li Q, Wang W, Sun Y, Xu Q and Gu Y: Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed Pharmacother. 68:751–756. 2014. View Article : Google Scholar : PubMed/NCBI
45	Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A and Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 187:129–134. 1998. View Article : Google Scholar : PubMed/NCBI
46	Basset L, Chevalier S, Danger Y, Arshad MI, Piquet-Pellorce C, Gascan H and Samson M: Interleukin-27 and IFNg regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. J Mol Med (Berl). 93:1355–1367. 2015. View Article : Google Scholar : PubMed/NCBI
47	Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al: Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology. 4:e10191972015. View Article : Google Scholar : PubMed/NCBI
48	Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER and Linette GP: Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 348:803–808. 2015. View Article : Google Scholar : PubMed/NCBI
49	Pizzurro GA and Barrio MM: Dendritic cell-based vaccine efficacy: Aiming for hot spots. Front Immunol. 6:912015. View Article : Google Scholar : PubMed/NCBI